LFB key figures
Employees committed on a daily basis
♦ 3,000 employees in the world in 2025
- More than 2,100 in France, including 1,600 in production
♦ More than 300 recruitments planned in 2025
♦ Nearly 50% of parity between women and men in 2025
An international bioproduction
♦ 6 bioproduction plants in the world, including 5 in France :
- Alès (Occitanie region)
- Arras (Hauts-de-France region)
- Carvin (Hauts-de-France region)
- Les Ulis (Ile-de-France region)
- Lille (Hauts-de-France region )
Biomedicinal products for serious and often rare diseases
♦ 2/3 of LFB biomedicinal products are intended for the treatment of patients with rare diseases
♦ About fifteen medicines marketed in about 30 countries.
♦ In 3 major therapeutical areas :
- Immunology,
- Haemostasis,
- Intensive Care.
Major industrial investments
750 million of euros invested in the new LFB plant in Arras (Hauts-de-France region)
- Medicinal products capacity multiplied by 3.
20 million of euros invested to double the production capacity at the Alès site (Occitanie region)
- Manufacturing of monoclonal antibodies multipled by 2.
- Manufacturing of active substances multiplied by 3.
